Valneva (NASDAQ:VALN) Shares Up 11.1% - What's Next?

Shares of Valneva SE (NASDAQ:VALN - Get Free Report) shot up 11.1% during trading on Monday . The stock traded as high as $6.99 and last traded at $6.99. 7,533 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 36,559 shares. The stock had previously closed at $6.29.

Analyst Ratings Changes

A number of equities research analysts recently commented on VALN shares. Guggenheim decreased their target price on Valneva from $17.00 to $15.00 and set a "buy" rating on the stock in a research report on Monday, March 24th. HC Wainwright restated a "buy" rating and issued a $17.00 price target on shares of Valneva in a research report on Tuesday.

Valneva Stock Up 3.3 %

The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The company has a 50 day simple moving average of $6.97 and a two-hundred day simple moving average of $5.66. The company has a market capitalization of $551.76 million, a P/E ratio of -52.23 and a beta of 1.85.

Valneva (NASDAQ:VALN - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The company had revenue of $56.48 million for the quarter, compared to analysts' expectations of $55.64 million. As a group, equities analysts predict that Valneva SE will post 0.13 EPS for the current year.

Hedge Funds Weigh In On Valneva

A number of large investors have recently bought and sold shares of the business. ABC Arbitrage SA bought a new stake in shares of Valneva during the fourth quarter worth $84,000. Wells Fargo & Company MN lifted its holdings in Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after buying an additional 30,859 shares in the last quarter. Finally, GAMMA Investing LLC purchased a new stake in Valneva in the 1st quarter valued at about $94,000. Hedge funds and other institutional investors own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.